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Abstract TNF-a is one of the key proinflammatory
cytokines in pathogenesis of rheumatoid arthritis (RA).
TNF-a was also found to enhance synthesis of leptin.
Leptin is mainly adipocyte-derived hormone controlling
appetite and energy expenditure. It acts through inhibition
of neuropeptide Y secretion. It is possible that TNF-a-
induced leptin secretion contributes to body mass reduction
in patients with RA. The study was designed to determine
the influence of inactivation of the TNF-a with infliximab
on plasma leptin and neuropeptide Y concentrations in
patients with RA. Sixteen female patients with RA treated
with infliximab and 16 healthy women were investigated.
Plasma leptin and neuropeptide Y concentrations were
determined before, during and after 1 year management of
the patients with infliximab and were compared with body
mass index and body fatty and lean mass. There was no
difference in plasma leptin concentration between the
rheumatoid patients before therapy and the controls
(15.6 ± 1.85 and 14.5 ± 2.15 ng/ml, respectively). Neu-
ropeptide Y concentration was higher in the patients than in
the controls (54.5 ± 3.96 and 24.8 ± 2.80 pmol/l,
respectively). Treatment with infliximab resulted in
enhancement in leptin concentration (18.5 ± 2.34 ng/ml)
and a slight increase in neuropeptide Y concentration
(58.7 ± 4.66 pmol/l). Physiological relationship between
leptin and body mass was shown in the patients and was
not altered during the treatment. There was no significant
correlation between the disease activity and plasma leptin
or neuropeptide Y concentrations.
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Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease and is associated with reduction of the body mass of
some of the patients. Pathomechanism of body mass
reduction that occurs in patients with chronic inflammatory
diseases remains still unclear.
TNF-a is one of the main proinflammatory cytokines
that plays a key role in pathogenesis of rheumatoid
arthritis. It has been shown that TNF-a increases secretion
of leptin, as known as ob protein, hormone produced
mainly by adipocytes, as well as the hormone that
decreases appetite and food intake by inhibition of neuro-
peptide Y (NPY) secretion [1, 2]. Leptin inhibits releasing
some other orexigenic (stimulating the appetite) neuro-
transmitters such as galanin [3], orexin A and B [4] or
agouti-related protein [5] and simultaneously increases
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level of some anorexigenic factors such as corticoliberin
[6], glucagon-like peptide-1 [7], melanotropin [8] and
cocaine- and amphetamine-regulated transcript. Many
studies focus on the role of leptin as a specific lipostat
because it inhibits directly accumulation of the intracellular
lipids by reducing the synthesis of fatty acids and triglyc-
erides and lowering oxidation of fatty acids [9]. It has been
also shown that leptin increases energy expenditure by
inhibiting oxidative phosphorylation [10]. Under physio-
logical conditions, plasma leptin concentration correlates
with mass of fatty tissue [11] and depends on gender, and a
higher leptin concentration was shown in women [12, 13].
There are more and more reports indicating influence of
TNF-a on increase in the ob gene expression and leptin
synthesis [14]. It has been suggested that cytokine-depen-
dent hyperleptinaemia may be a potential cause of body
mass reduction in patients with RA. Chronic long-term
administration of TNF-a to mice resulted in lowering of
body mass [15–18].
Infliximab, a chimeric monoclonal antibody acting by
blocking both soluble and cell membrane-bound forms of
TNF-a, is widely used for treatment of patients with RA
[19]. The aim of the study was evaluation of the effect of
infliximab on plasma leptin and neuropeptide Y concen-
trations in patients with RA.
Patients and methods
The study group consisted of 16 female patients with RA
treated with infliximab (Remicade). All of them were in the
postmenopausal period and did not receive hormonal
replacement therapy.
Sixteen age—body mass index (BMI)—matched healthy
women were investigated as the controls. All patients have
active disease and had not received remission after application
of at last two disease-modified drugs. Infliximab treatment
was administered 7.1 ± 1.0 years after onset of arthritis.
Infliximab was administered intravenously in a dose of 3 mg/
kg of body mass as 2-h infusion. The infusions were repeated
after 2 and 6 weeks after the first infusion, and subsequently
every 8 weeks (to total number of infusions–9).
Patients were also given prednisone in a dose of
5.7 ± 1.08 mg/day and methotrexate in a dose of
9.3 ± 0.53 mg/week. All patients received folic acid in the
dose of 5 mg/day. The patients were not treated with folic
acid during the day they were receiving methotrexate.
At least 4 weeks before the beginning of therapy with
infliximab, during the whole period of treatment and
8 weeks after the 9th infusion of infliximab, the doses of
additional medication were unchanged.
Only female patients, which on the basis of clinical
examination and results of additional tests were possible to
exclude potential factors that might have some influence on
the body mass and plasma leptin concentration, that is,
thyroid disorders, other endocrinopathy, renal insuffi-
ciency, heart failure, arterial hypertension, diabetes melli-
tus, hyperlipidemia, neoplastic disease or mental disease,
were included in this study. None of those patients smoked
cigarettes.
Plasma leptin and neuropeptide Y concentrations were
measured: before treatment, after first infusion, after sec-
ond infusion (i.e. 2 weeks from first infusion), after fourth
infusion (i.e. 14 weeks from beginning of therapy), after
sixth infusion (i.e. 30 weeks from beginning of therapy),
after ninth dose (i.e. 54 weeks from beginning of therapy)
and in follow-up, that is, 62 weeks from the beginning of
therapy. Blood samples were taken in the morning (8.00
AM) after overnight fasting. Plasma was stored at -20C.
In patients treated with infliximab, blood samples were
drawn in the next day after the drug infusion. Plasma leptin
concentration was measured with radioimmunoassay
method (Human leptin RIA KIT from Linco Research Inc.
USA) and plasma NPY concentration using radioimmu-
noassay method with Euria-NPY kit (Euro-Diagnostica
Sweden).
The following indices were determined: body mass,
body mass index (BMI) and waist-to-hip ratio (WHR).
Content of fatty tissue and lean mass was determined with
densitometric method before and after treatment (DEXA
Dual Energy X-ray Absorptiometry, Lunar DPXL). Den-
sitometric measurements (mass of fatty tissue and lean
mass) and the determination of WHR took place only in
patients treated with infliximab.
Erythrocyte sedimentation rate (ESR), C-reactive pro-
tein (CRP) level and platelet count (PLT) were assayed
with routine used methods. DAS 28 was calculated as the
disease activity index.
Statistical analysis Results were expressed as
mean ± standard error of mean (SEM). Fisher‘s test was
used to analyse normal distribution of data, and Student‘s
t-test and U Mann–Whitney test were used appropriately.
Correlation analysis was performed using Pearson‘s coef-
ficient or Kendall tau coefficient calculation.
Results
Mean plasma leptin concentration is shown in Fig. 1. There
was no difference between rheumatoid patients before
infliximab treatment and the controls. An increase in
plasma leptin concentration was found after the 1st, 2nd
and 4th infusion of infliximab. It was followed by some
decrease in leptin concentration; thus, plasma leptin (after
the 6th and 9th infusion) and enhanced plasma leptin were
shown 8 weeks after the last infusion.
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Plasma NPY concentration in rheumatoid patients
before the medication with infliximab was almost twice
higher than in healthy controls (Fig. 2). NPY concentration
was shown to be high during the treatment with infliximab,
and additional increase in NPY concentration was found
after 6th and 9th infusion. Eight weeks after the last infu-
sion, NPY concentration was still enhanced but slightly
reduced as compared with NPY concentration after the 6th
infusion.
CRP, ESR and PLT were higher in the rheumatoid
patients. During the medication with infliximab, a signifi-
cant reduction in CRP, ESR and PLT was found; also, the
results shown after the 9th infusion, that is, 8 weeks after
the last infusion, were still higher than the normal values
(data not shown).
BMI of the RA patients was 26.0 ± 1.29 kg/m2 before
the treatment with infliximab. There was no difference in
BMI after the medication although some increasing ten-
dency was shown (BMI, 8 weeks after the last infusion
26.6 ± 1.23 kg/m2). Similar tendency was observed in
body mass (69.2 ± 3.64 kg before the treatment,
70.8 ± 3.44 kg 8 weeks after the last infusion) and waist-
to-hip ratio (0.81 ± 0.01 versus 0.83 ± 0.01).
Leptin/BMI ratio was found to shown increasing ten-
dency during the treatment. In the patients before
infliximab medication, the ratio was 0.57 ± 0.04, while
after the treatment was 0.66 ± 0.07. The leptin/BMI ratio
in the controls was 0.53 ± 0.06.
Determination of fatty tissue and lean mass was carried
out in RA patients before and after infliximab therapy.
Results are summarised in Table 1. An increase in total
body mass of fatty tissue as well as fatty tissue of the upper
and lower limbs was found. The increase was accompanied
by a slight decrease in lean mass of the trunk and upper
limbs (Table 1).
Plasma leptin concentration was found to be positively
correlated with BMI both in controls and in patients before
and during medication with infliximab (Table 2). Leptin
was also found to correlate with body mass and total body
fatty mass tissue, lean mass and waist-to-hip ratio
(Table 3). There was no correlation between either plasma
NPY and BMI or leptin and NPY. There was no correlation
between plasma NPY and body mass and fatty tissue mass,
except positive correlation between NPY and fatty mass of
the trunk (s = 0.478, P \ 0.012), fatty mass of the lower
limbs (s = 0.382, P \ 0.046) and waist-to-hip ratio
(s = 0.495, P \ 0.007) all after treatment. There was also
no correlation between plasma leptin concentration and
inflammatory indices (CRP, ESR and PLT) as well as
diseases activity (DAS 28), but 8 weeks after the last
Fig. 1 The plasma leptin
concentrations in control and
study groups before treatment,
during the treatment and after
the treatment with infliximab
(mean values ± SEM)
Fig. 2 The plasma
neuropeptide Y concentrations
in the control group and in the
study group before the
treatment, during the therapy
and after the treatment with
infliximab (mean
values ± SEM)
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infusion, a positive correlation was found (leptin versus
DAS28, s = 0.433, P \ 0.041).
A positive correlation between plasma NPY concen-
tration and inflammatory indices was shown only before
medication (NPY versus CRP, s = 0.506, P \ 0.006; NPY
versus DAS 28, s = 0.393, P \ 0.033). There was no
correlation between inflammatory indices and body indices
(body mass, BMI, WHR, total fatty tissue and total lean
mass). Multivariate regression analysis performed with
dependent variable—plasma leptin concentration—and
independent variables—BMI, WHR, total body fatty tissue
mass, total body lean mass, CRP, ESR, PLT, DAS 28 score
and plasma NPY concentration—in patients with RA
treated with infliximab revealed significant positive cor-
relation between plasma leptin concentration and total
body fatty tissue mass and significant negative correlation
between plasma leptin concentration and total body lean
mass (Table 4).
Discussion
The obtained results indicate for lack of difference in
plasma leptin concentration between RA patients and
healthy individuals. This finding is concomitant with
reports of Nishiya et al. [20], Popa et al. [21, 22] and
Anders et al. [23]. The last investigators additionally
reported lack of changes in plasma leptin concentration in
RA patients before and after treatment with infliximab. On
the contrary, Tokarczyk-Knapik et al. [24] reported
decreased plasma leptin in patients with RA. A possible
source of this discrepancy may be BMI of the RA patients
in the study of Tokarczyk-Knapik et al. [24]. Their BMI
was lower than that of the control group. Otero et al. [25]
reported that patients with RA showed higher plasma leptin
























































































































































































































































































































































































































































































































Table 2 Correlation between plasma leptin concentration and body
mass index in control group and in study group before the treatment
and after sequential infusions of infliximab
Correlation s P
Leptin/BMI CG 0.545 0.003
Leptin/BMI RAbefore 1st infusion 0.533 0.004
Leptin/BMI RA1 0.516 0.005
Leptin/BMI RA2 0.483 0.009
Leptin/BMI RA4 0.437 0.018
Leptin/BMI RA6 0.393 0.033
Leptin/BMI RA9 0.483 0.009
Leptin/BMI RAafter treatment 0.383 0.038
CG control group, RA before 1st RA group before 1st infusion of
infliximab, RA1,2,4,6,9 RA group after sequential infusions,RAafter tr
RA group after the treatment
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Gonzalez-Gay et al. [26] showed that anti-TNF-a ther-
apy does not modulate leptin concentration in patients with
severe rheumatoid arthritis. In the present study, we
reported an increase in plasma leptin concentration in RA
patients after management with infliximab. An increase
was shown even after the first infusion of the drug and
lasted after medication. The enhanced plasma leptin con-
centration after the first infusions cannot be associated with
an increase in BMI of the patients. Some increase in BMI
was shown at least after the 4th infusion of infliximab. The
observation is similar to report of van Gossum et al. [27]
who reported plasma leptin increase after 1 and 4 weeks of
infliximab treatment of patients with Crohn disease. It is
possible that changes in TNF-a level in RA patients during
medication with infliximab are very rapid but transient
after early infusions or TNF-a release in inflammatory
states has pulsatory nature. It has been shown in vitro that
TNF-a has diphasic effect on leptin secretion by
adipocytes. Some studies revealed that TNF-a causes only
transitory elevated plasma leptin concentration followed by
decreased releasing of this hormone. It was shown in in
vitro experiments, and this phenomenon is suggested to be
explained as the chronic influence of cachectin on distur-
bance in adipocytes differentiation leading to impairment
in leptin production [28]. Granowitz [29] suggested that
TNF-a enhances leptin secretion only in cooperation with
transforming growth factor-b and TNF-a alone is less
potent stimulatory or even exerts inhibitory properties. It is,
however, very difficult to use data from in vitro investi-
gations for explanation of phenomena observed in the RA
patients. TNF-a was not determined in our study, but
clinical efficacy of medication strongly suggests that active
TNF-a level at least in the joints was diminished.
Plasma NPY concentration was found to be higher in
patients with RA. Treatment with infliximab was associ-
ated with some further enhancement of plasma NPY. An
increase in plasma NPY concentration in RA can be
explained by higher sympathetic activity in RA as it was
shown by Dekkers et al. [30].
As expected, some increase in BMI in the RA patients
was found after the treatment. This finding is concomitant
with other reports [27]. The correlation of plasma leptin
concentration with BMI was shown to be unchanged in the
RA patients before and during the infliximab medication.
Plasma leptin concentration was shown to correlate with fat
mass and unexpectedly with lean mass after infliximab
treatment. There was no significant correlation between
plasma leptin concentration, inflammatory indices and
disease activity. Similar results were reported by other
authors [20, 23, 24]. Only Targon´ska-Ste˛pniak et al. [31]
showed positive correlation between plasma leptin
Table 3 The correlation between plasma leptin concentration and total body weight, total body fatty tissue mass, lean mass and waist-to-hip
ratio before and after therapy with infliximab and between plasma leptin concentration and body weight after sequential infusions of infliximab
s P s P
Leptin/body weight 0.633 0.000 0.493 0.007
Leptin/total body fatty tissue 0.717 0.000 0.523 0.006
Leptin/total body lean mass 0.461 0.028 0.142 NS
Leptin/fatty tissue mass of the trunk 0.692 0.001 0.542 0.004
Leptin/lean mass of the trunk 0.512 0.014 0.314 NS
Leptin/fatty tissue mass of upper limbs 0.615 0.003 0.581 0.002
Leptin/lean mass of upper limbs 0.512 0.014 0.200 NS
Leptin/fatty tissue mass of lower limbs 0.589 0.005 0.333 NS
Leptin/lean mass of lower limbs 0.307 NS -0.047 NS











s = 0.583 P = 0.001 s = 0.533 P = 0.004 s = 0.531 P = 0.004 s = 0.393 P = 0.033 s = 0.477 P = 0.010
NS not statistically significant
Table 4 Multivariate regression analysis with dependent variable—
plasma leptin concentration—and independent variables—body mass
index (BMI), waist-to-hip ratio (WHR), total body fatty tissue mass,
total body lean mass, CRP, ESR, platelet count (PLT), DAS28 score
and plasma neuropeptide Y concentration in patients with rheumatoid
arthritis (R2 = 0.724); only variables that have statistically signifi-
cant influence on plasma leptin concentration, after elimination of
insignificant variables in sequential parts of regression analysis, are
shown
Study parameter Study group
Total body fatty tissue mass b 0.001
P 0.000
Total body lean mass b -0.000
P 0.013
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concentration and DAS28. Popa et al. [21] found inversed
correlation between plasma leptin and serum C-reactive
protein and interleukin-6 concentration in RA patients.
There was no significant correlation between plasma leptin
and NPY concentrations.
In summary, it can be concluded that plasma leptin
concentration is not significantly altered in RA patients.
Infusion of infliximab, anti-TNF-a antibody, produces an
increase in plasma leptin that probably is resulted from
transient rapid reduction of serum TNF-a. After longer
medication, plasma leptin changes are related to BMI in
similar pattern as under physiological conditions in healthy
individuals.
Further investigations including studies on RA patients
with significant body mass deficiency are needed to elu-
cidate leptin–inflammation relationship in RA.
Conclusion
Plasma leptin concentration in patients with rheumatoid
arthritis does not differ from healthy individuals. Plasma
NPY concentration in patients with rheumatoid arthritis is
higher than in healthy individuals. During the therapy with
infliximab, a TNF-a antagonist, plasma leptin concentra-
tion increases, and there were no changes in plasma NPY
concentration during therapy.
In patients with rheumatoid arthritis, physiological
relation between plasma leptin concentration and body
mass (BMI, fatty tissue mass) is unaltered. The treatment
with infliximab does not disturb this correlation.
In patients with rheumatoid arthritis treated with inf-
liximab, the disease activity does not correlate with plasma
leptin concentration. There is no significant correlation
between the disease activity and plasma NPY concentra-
tion in those patients revealed.
It does not seem that leptin plays a crucial role in the
reduction of the body mass in patients with rheumatoid
arthritis.
Open Access This article is distributed under the terms of the
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